Header Logo

Connection

Anthony Rothschild to Antipsychotic Agents

Back to Details
This is a "connection" page, showing publications Anthony Rothschild has written about Antipsychotic Agents.
Anthony Rothschild
Connection Strength
6.480
Antipsychotic Agents
  1. Cintr?n Pastrana MA, Irizarry Flores JC, Rothschild AJ. Challenges in the Treatment of Psychotic Bipolar Depression. J Clin Psychopharmacol. 2024 Jul-Aug 01; 44(4):407-412.
    View in: PubMed
    Score: 0.745
  2. Rothschild AJ. Maintenance treatment of psychotic depression: Is antipsychotic medication needed? Acta Psychiatr Scand. 2024 01; 149(1):3-5.
    View in: PubMed
    Score: 0.721
  3. Rothschild AJ. Should Antipsychotic Medications Be Prescribed to Patients With Nonpsychotic Depression? J Clin Psychopharmacol. 2022 May-Jun 01; 42(3):231-233.
    View in: PubMed
    Score: 0.641
  4. Rothschild AJ. Why Is There No Food and Drug Administration-Approved Medication for Major Depression With Psychotic Features? J Clin Psychopharmacol. 2021 Jul-Aug 01; 41(4):359-361.
    View in: PubMed
    Score: 0.606
  5. Rothschild AJ. Challenges in the treatment of major depressive disorder with psychotic features. Schizophr Bull. 2013 Jul; 39(4):787-96.
    View in: PubMed
    Score: 0.343
  6. de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer J, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):179-196.
    View in: PubMed
    Score: 0.197
  7. de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer JM, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):197-218.
    View in: PubMed
    Score: 0.197
  8. Carter E, Banerjee S, Alexopoulos GS, Bingham KS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ. Prediction of remission of pharmacologically treated psychotic depression: A machine learning approach. J Affect Disord. 2025 Jul 15; 381:291-297.
    View in: PubMed
    Score: 0.197
  9. Kim HK, Voineskos AN, Neufeld NH, Alexopoulos GS, Bingham KS, Flint AJ, Marino P, Rothschild AJ, Whyte EM, Mulsant BH. Effect of olanzapine exposure on relapse and brain structure in patients with major depressive disorder with psychotic features. Mol Psychiatry. 2024 Aug; 29(8):2459-2466.
    View in: PubMed
    Score: 0.183
  10. Tani H, Moxon-Emre I, Forde NJ, Neufeld NH, Bingham KS, Whyte EM, Meyers BS, Alexopoulos GS, Hoptman MJ, Rothschild AJ, Uchida H, Flint AJ, Mulsant BH, Voineskos AN. Brain metabolite levels in remitted psychotic depression with consideration of effects of antipsychotic medication. Brain Imaging Behav. 2024 Feb; 18(1):117-129.
    View in: PubMed
    Score: 0.178
  11. Neufeld NH, Oliver LD, Mulsant BH, Alexopoulos GS, Hoptman MJ, Tani H, Marino P, Meyers BS, Rothschild AJ, Whyte EM, Bingham KS, Flint AJ, Voineskos AN. Effects of antipsychotic medication on functional connectivity in major depressive disorder with psychotic features. Mol Psychiatry. 2023 Aug; 28(8):3305-3313.
    View in: PubMed
    Score: 0.173
  12. Men X, Marshe V, Elsheikh SS, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Rothschild AJ, Voineskos AN, Whyte EM, Kennedy JL, Flint AJ, M?ller DJ. Genomic Investigation of Remission and Relapse of Psychotic Depression Treated with Sertraline plus Olanzapine: The STOP-PD II Study. Neuropsychobiology. 2023; 82(3):168-178.
    View in: PubMed
    Score: 0.171
  13. Rothschild AJ, Duval SE. How long should patients with psychotic depression stay on the antipsychotic medication? J Clin Psychiatry. 2003 Apr; 64(4):390-6.
    View in: PubMed
    Score: 0.171
  14. Song J, Mulsant BH, Sanches M, Alexopoulos GS, Marino P, Meyers BS, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Gerretsen P. Residual or re-emergent impaired insight into delusions following remission is unrelated to later relapse during a randomized clinical trial of continuation pharmacotherapy for psychotic depression - The STOP-PD II Study. J Affect Disord. 2023 03 15; 325:29-34.
    View in: PubMed
    Score: 0.168
  15. Flint AJ, Bingham KS, Alexopoulos GS, Marino P, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Meyers BS. Predictors of relapse of psychotic depression: Findings from the STOP-PD II randomized clinical trial. J Psychiatr Res. 2023 01; 157:285-290.
    View in: PubMed
    Score: 0.168
  16. Flint AJ, Rothschild AJ, Whyte EM, Alexopoulos GS, Mulsant BH, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Meyers BS. Effect of Older vs Younger Age on Anthropometric and Metabolic Variables During Treatment of Psychotic Depression With Sertraline Plus Olanzapine: The STOP-PD II Study. Am J Geriatr Psychiatry. 2021 07; 29(7):645-654.
    View in: PubMed
    Score: 0.145
  17. Voineskos AN, Mulsant BH, Dickie EW, Neufeld NH, Rothschild AJ, Whyte EM, Meyers BS, Alexopoulos GS, Hoptman MJ, Lerch JP, Flint AJ. Effects of Antipsychotic Medication on Brain Structure in Patients With Major Depressive Disorder and Psychotic Features: Neuroimaging Findings in the Context of a Randomized Placebo-Controlled Clinical Trial. JAMA Psychiatry. 2020 07 01; 77(7):674-683.
    View in: PubMed
    Score: 0.141
  18. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Alexopoulos GS, Rudorfer MV, Marino P, Banerjee S, Pollari CD, Wu Y, Voineskos AN, Mulsant BH. Effect of Continuing Olanzapine vs Placebo on Relapse Among Patients With Psychotic Depression in Remission: The STOP-PD II Randomized Clinical Trial. JAMA. 2019 08 20; 322(7):622-631.
    View in: PubMed
    Score: 0.133
  19. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry. 1999 Feb; 60(2):116-8.
    View in: PubMed
    Score: 0.128
  20. ?stergaard SD, Meyers BS, Flint AJ, Mulsant BH, Whyte EM, Ulbricht CM, Bech P, Rothschild AJ. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. J Affect Disord. 2014 May; 160:68-73.
    View in: PubMed
    Score: 0.090
  21. Blumberger DM, Mulsant BH, Kanellopoulos D, Whyte EM, Rothschild AJ, Flint AJ, Meyers BS. The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression. J Clin Psychopharmacol. 2013 Jun; 33(3):391-7.
    View in: PubMed
    Score: 0.087
  22. Flint AJ, Iaboni A, Mulsant BH, Rothschild AJ, Whyte EM, Meyers BS. Effect of sertraline on risk of falling in older adults with psychotic depression on olanzapine: results of a randomized placebo-controlled trial. Am J Geriatr Psychiatry. 2014 Apr; 22(4):332-6.
    View in: PubMed
    Score: 0.086
  23. Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Mulsant BH, Rudorfer MV, Marino P. Sustaining remission of psychotic depression: rationale, design and methodology of STOP-PD II. BMC Psychiatry. 2013 Jan 25; 13:38.
    View in: PubMed
    Score: 0.084
  24. Weissman J, Flint A, Meyers B, Ghosh S, Mulsant B, Rothschild A, Whyte E. Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression. Psychiatry Res. 2012 May 30; 197(3):221-6.
    View in: PubMed
    Score: 0.080
  25. Blumberger DM, Mulsant BH, Emeremni C, Houck P, Andreescu C, Mazumdar S, Whyte E, Rothschild AJ, Flint AJ, Meyers BS. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatr Res. 2011 Jul; 45(7):896-901.
    View in: PubMed
    Score: 0.074
  26. Andreescu C, Mulsant BH, Peasley-Miklus C, Rothschild AJ, Flint AJ, Heo M, Caswell M, Whyte EM, Meyers BS. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007 Feb; 68(2):194-200.
    View in: PubMed
    Score: 0.056
  27. Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res. 2006 Sep; 86(1-3):234-43.
    View in: PubMed
    Score: 0.054
  28. Ihaddadene RA, Alexopoulos GS, Marino P, Meyers BS, Mulsant BH, Neufeld NH, Rothschild AJ, Voineskos AN, Whyte EM, Flint AJ, Bingham KS. Predictors of attrition during acute pharmacotherapy of psychotic depression in a clinical trial. Psychiatry Res. 2024 Dec; 342:116192.
    View in: PubMed
    Score: 0.047
  29. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry. 2003 Apr 15; 53(8):680-90.
    View in: PubMed
    Score: 0.043
  30. Patel DA, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS, Mulsant BH, Voineskos AN, Marino P, Alexopoulos GS. Pharmacotherapy Prescriptions for Relapse Prevention of Psychotic Depression After Electroconvulsive Therapy. J Clin Psychopharmacol. 2021 Mar-Apr 01; 41(2):196-199.
    View in: PubMed
    Score: 0.037
  31. Zarate CA, Rothschild A, Fletcher KE, Madrid A, Zapatel J. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry. 2000 Mar; 61(3):185-9.
    View in: PubMed
    Score: 0.035
  32. Bingham KS, Meyers BS, Mulsant BH, Rothschild AJ, Whyte EM, Banerjee S, Artis AS, Alexopoulos GS, Flint AJ. Stabilization treatment of remitted psychotic depression: the STOP-PD study. Acta Psychiatr Scand. 2018 09; 138(3):267-273.
    View in: PubMed
    Score: 0.031
  33. Bingham KS, Rothschild AJ, Mulsant BH, Whyte EM, Meyers BS, Banerjee S, Szanto K, Flint AJ. The Association of Baseline Suicidality With Treatment Outcome in Psychotic Depression. J Clin Psychiatry. 2017 Sep/Oct; 78(8):1149-1154.
    View in: PubMed
    Score: 0.029
  34. Victoria LW, Whyte EM, Butters MA, Meyers BS, Alexopoulos GS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Improvement in Depression is Associated with Improvement in Cognition in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2017 Jun; 25(6):672-679.
    View in: PubMed
    Score: 0.028
  35. Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am. 1996 Jun; 19(2):237-52.
    View in: PubMed
    Score: 0.027
  36. Davies SJ, Mulsant BH, Flint AJ, Meyers BS, Rothschild AJ, Whyte EM, Kirshner MM, Sorisio D, Pollock BG, Bies RR. SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study. Hum Psychopharmacol. 2016 05; 31(3):252-5.
    View in: PubMed
    Score: 0.026
  37. ?stergaard SD, Rothschild AJ, Flint AJ, Mulsant BH, Whyte EM, Vermeulen T, Bech P, Meyers BS. Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). J Affect Disord. 2016 Jan 15; 190:111-114.
    View in: PubMed
    Score: 0.026
  38. Bingham KS, Whyte EM, Meyers BS, Mulsant BH, Rothschild AJ, Banerjee S, Flint AJ. Relationship Between Cerebrovascular Risk, Cognition, and Treatment Outcome in Late-Life Psychotic Depression. Am J Geriatr Psychiatry. 2015 Dec; 23(12):1270-1275.
    View in: PubMed
    Score: 0.025
  39. Davies SJ, Mulsant BH, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS. Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study. Compr Psychiatry. 2014 Jul; 55(5):1069-76.
    View in: PubMed
    Score: 0.023
  40. Deligiannidis KM, Rothschild AJ, Barton BA, Kroll-Desrosiers AR, Meyers BS, Flint AJ, Whyte EM, Mulsant BH. A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures. J Clin Psychiatry. 2013 Oct; 74(10):1003-9.
    View in: PubMed
    Score: 0.022
  41. Rothschild AJ, Samson JA, Bessette MP, Carter-Campbell JT. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression. J Clin Psychiatry. 1993 Sep; 54(9):338-42.
    View in: PubMed
    Score: 0.022
  42. Meyers BS, Flint AJ, Rothschild AJ, Mulsant BH, Whyte EM, Peasley-Miklus C, Papademetriou E, Leon AC, Heo M. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry. 2009 Aug; 66(8):838-47.
    View in: PubMed
    Score: 0.017
  43. Meyers BS, English J, Gabriele M, Peasley-Miklus C, Heo M, Flint AJ, Mulsant BH, Rothschild AJ. A delusion assessment scale for psychotic major depression: Reliability, validity, and utility. Biol Psychiatry. 2006 Dec 15; 60(12):1336-42.
    View in: PubMed
    Score: 0.014
  44. Sit D, Rothschild AJ, Wisner KL. A review of postpartum psychosis. J Womens Health (Larchmt). 2006 May; 15(4):352-68.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.